Metronomic Decitabine-Cedazuridine and Venetoclax in R/R AML, HR-MDS, HR/AP MPN

This is a single-center randomized phase 2 open-label clinical trial.

Trial Details

NCT ID
NCT07710534
Phase
PHASE2
Sponsor
Virginia Commonwealth University
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • Decitabine-cedazuridine plus venetoclax (DEC-C+VEN)
  • Azacitidine plus venetoclax (AZA+VEN)
Locations (sample)
  • Richmond, Virginia, United States|37.55376,-77.46026

Key Eligibility Criteria

  • Age ≥18 years at time of enrollment
  • Diagnosis of one of the following by World Health Organization (WHO) International Consensus Classification (ICC) criteria as determined by local a…
  • Relapsed/ refractory acute myeloid leukemia (R/R AML) as defined by ≥5% marrow blasts or unequivocal, measurable extramedullary disease
  • High Risk Myelodysplastic Syndrome (HR-MDS) (high/very high risk MDS by Revised International Prognostic Scoring System (IPSS-R) or Molecular Inter…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →